Разработка генератора холодной плазмы для нуклеопластики

В настоящей работе мы исследовали низкотемпературную плазму и ее параметры для разработки генератора холодной плазмы для нуклеопластики. На первом этапе нашей исследовательской работы мы изучили более 20-ти патентов на приборы, основной функцией которых являлось образование холодной плазмы в электролитах. Мы выявили наиболее приемлемые параметры разрабатываемого нами генератора, а также следующие особенности: 1.Плазма формируется в электролите. 2.Для нуклеопластики используется малый размер электрода. 3.Необходимость возбуждения и удержания режима плазмы. 4.Для режима плазмы требуется меньше мощность, чем для нагрева проводящей ткани от прохождения переменного тока высокой частоты

Registration and processing system of digital speckle images

In this paper, we discuss an application of the method of laser-speckle correlation for studying the blood coagulation process. A module for recording and processing speckle images based on a debugging kit for the Atxmega128A1 microcontroller has been developed. The results of testing the developed module as part of a laboratory setup based on a semiconductor laser using standard reagents are presented

Pre-Clinical Studies of Inactivated Polivalent Vaccine Against Hemorrhagic Fever with Renal Syndrome

Relevance. Hemorrhagic fever with renal syndrome (HFRS) is a non-transmissible viral zoonosis widespread in Eurasia, and in Russia it occupies a leading position among zoonotic viral infections and one of the first places among all natural focal human diseases. Aim. Obtaining evidence of the safety, quality and efficacy of a polyvalent vaccine against HFRS as a result of its preclinical studies using scientific assessment methods that meet the requirements and rules of good laboratory practice. Materials and methods. For preclinical studies of the polyvalent vaccine against HFRS, the materials and methods were used in strict accordance with the requirements of the regulatory documents, as well as previously described methods used to control the vaccine at the technological stages of its manufacture. Results. The data obtained as a result of preclinical studies of the polyvalent vaccine agains HFRS indicate a high immunogenicity and stability of the vaccine, the absence of: acute and chronic toxicity, allergenic, immunotoxic and mutagenic, as well as toxic effects on the reproductive organs of animals, embryo development and offspring, born to females who received the vaccine within 20 days of gestation. Conclusion. The obtained results of preclinical studies comply with the requirements for immunobiological medical preparations designed for humans, and are the basis for conducting the 1st phase of clinical trials the polyvalent vaccine against HFRS

The elemental abundance pattern of twenty

Detailed elemental abundances were derived for twenty bona fide λ Bootis as well as two MK standard stars. Other than LTE abundances for ten elements (including C and O), NLTE values for Na were determined. The group of λ Bootis stars consists of non-magnetic, Population I, late B to early F-type dwarfs with a typical abundance pattern (Fe-peak elements being underabundant whereas C, N, O and S being almost solar abundant). Since classification resolution spectroscopy in the optical domain is not capable of determining the abundance of the light elements, a detailed abundance analysis is the ultimate test for the membership of an object to this group. Another important point is the detection of apparent spectroscopic binary systems in which two solar abundance objects mimic one metal-weak star, as proposed as a working hypothesis by Faraggiana & Bonifacio (1999). From twenty program stars we are able to confirm or establish the membership for nine objects (HD 23258, HD 36726, HD 40588, HD 74911, HD 84123, HD 91130, HD 106223, HD 111604 and HD 290799). Five stars (HD 90821, HD 98772, HD 103483, HD 108765 and HD 261904) can be definitely ruled out as being members of the λ Bootis group whereas no unambiguous decision can be drawn for another six stars (HD 66684, HD 105058, HD 120500, HD 141851, HD 201184 and HD 294253). One very important result is the apparent overabundances found for Na which cannot be explained by accretion or mass-loss alone

Hemorrhagic Fever with Renal Syndrome (History, problems and Research Perspectives)

The work is devoted to clarify the etiological aspects of the hemorrhagic fever with renal syndrome (HFRS), clinical and epidemiological features that are closely linked to the etiology, as well as to development of methods and products for specific diagnosis and vaccine prevention of hantavirus infection. That regard to hantaviruses a set of virological, immunological and molecular-genetics methods were developed significantly enhance the effectiveness of the specific diagnostics of HFRS. The features of humoral immunity in HFRS were identified and atypical clinical forms of HFRS was istablished; indicators of natural immunity to hantavirus in the population living in different regions of Russia and the former Soviet republics have been identified that allowed us to refine nosological area of HFRS; new, previously unknown natural foci of HFRS, including hantavirus RNA, in the central regions of Russia and in the subtropical zone of Krasnodar region have been identified and studied; 76 strains and 70 isolates of 9 rodent species and one species of birds, as well as from the blood of patients with HFRS and sectional materials from HFRS dead patients have been isolated and identified; new hantavirus species - Khabarovsk, Taimyr-Topografov, Adler, as well as two new genotypes Dobrava/Belgrad virus - Kurkino and Sochi have been identified; species composition of small mammals - the natural reservoir of hantaviruses was the refined; etiological role and epidemiological importance of different hantaviruse types in HFRS incidence structure was established; the existence of new etiologically distinct hantavirus infections with significant epidemiological differences has been proven; manufacturing techniques and methods of control of the culture inactivated vaccine against HFRS has been developed

Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18–60 and 60+ Age Cohorts

We present the results of a randomized, double-blind, placebo-controlled, multi-center clinical trial phase I/II of the tolerability, safety, and immunogenicity of the inactivated whole virion concentrated purified coronavirus vaccine CoviVac in volunteers aged 18–60 and open multi-center comparative phase IIb clinical trial in volunteers aged 60 years and older. The safety of the vaccine was assessed in 400 volunteers in the 18–60 age cohort who received two doses of the vaccine (n = 300) or placebo (n = 100) and in 200 volunteers in 60+ age cohort all of whom received three doses of the vaccine. The studied vaccine has shown good tolerability and safety. No deaths, serious adverse events (AEs), or other significant AEs related to vaccination have been detected. The most common AE in vaccinated participants was pain at the injection site (p p 1:256, the rate of fourfold increase in nAB levels was below 45%; the participants who were seropositive at screening of the 2nd vaccination did not lead to a significant increase in nAB titers. In conclusion, inactivated vaccine CoviVac has shown good tolerability and safety, with over 85% NT seroconversion rates after complete vaccination course in participants who were seronegative at screening in both age groups: 18–60 and 60+. In participants who were seropositive at screening and had nAB titers below 1:256, a single vaccination led to a fourfold increase in nAB levels in 85.2% of cases. These findings indicate that CoviVac can be successfully used both for primary vaccination in a two-dose regimen and for booster vaccination as a single dose in individuals with reduced neutralizing antibody levels